Small Molecule
for BIO 2024
Inhibition of the NF-kB signaling pathway is an attractive therapeutic target for various diseases and disorders involving immunity and inflammation, including autoimmune diseases, infections, stroke, diabetes, musculoskeletal injuries, arthofibrosis, and cancer. Treatment for inflammatory disease. There is a need for a more targeted drug delivery approach that will enable controlled, localized release of NF-kB immunomodulators as a therapeutic strategy for these diseases without off-target effects. 